Treatment & prevention of benign prostatic hyperplasia (BPH) progression by alleviation of symptoms, improvement of urinary flow rate, reduction of prostate size (vol) & risk of acute urinary retention & the need for BPH-related surgery.
Liver disease; cardiac failure. Perform digital rectal exam & other prostate cancer evaluations on BPH patients prior to therapy & periodically thereafter. Establish new PSA baseline after 6 mth of treatment. Regularly monitor & carefully evaluate any sustained increase of PSA values. Risk of prostate cancer & high grade tumor; orthostatic hypotension; intraoperative floppy iris syndrome. Discontinue therapy 1-2 wk prior to cataract surgery. Concomitant use w/ CYP3A4 & CYP2D6 inhibitors. Breast cancer in men. May affect ability to drive or operate machinery. Renal & hepatic impairment. Women & childn should avoid contact w/ leaking caps.
G04CA52 - tamsulosin and dutasteride ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.
Sign Out
